Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OncoMed, Lilly Enter Clinical Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

OncoMed, Lilly Enter Clinical Supply Pact

Will evaluate Alimta and carboplatin with Demcizumab in NSCLC

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OncoMed Pharmaceuticals, Inc. has entered into a clinical supply agreement with Eli Lilly and Co. to supply Alimta for OncoMed’s ongoing Phase II DENALI trial. The trial will evaluate Demcizumab, OncoMed’s anti-DLL4 antibody in combination with Lilly’s Alimta (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC).
 
Alimta is approved as an initial treatment in combination with cisplatin for locally advanced or metastatic NSCLC for patients with non-squamous histology. The DENALI trial aims to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors do not have an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation.
 
“This agreement with Lilly strengthens our efforts to investigate demcizumab as a key component alongside Alimta and platinum chemotherapy for the initial treatment of locally advanced or metastatic non-squamous non-small cell lung cancer,” said Paul J. Hastings, OncoMed’s chairman and chief executive officer. “These data will add to the growing body of research to determine whether certain three-drug combinations may help improve patient outcomes.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics